- Exelixis Inc (NASDAQ:EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS).
- CONTACT-03 is sponsored by Roche Holdings AG (OTC:RHHBY) and co-funded by Exelixis.
- The study evaluated Cabometyx (cabozantinib) combined with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear or non-clear renal cell carcinoma who progressed during or after immune checkpoint inhibitor therapy.
- Three months ago, the companies disclosed a similarly disappointing outcome for the CONTACT-01 study.
- Tecentriq plus Cabometyx failed to meet its primary endpoint of overall survival at the final analysis compared to chemotherapy.
- CONTACT-02, focused on metastatic castration-resistant prostate cancer, is slated to read out later this year.
- The CONTACT-03 trial enrolled 522 patients with locally advanced or metastatic clear cell or non-clear cell renal cell carcinoma who progressed during or after immune checkpoint inhibitor therapy, either as part of a combination or as a monotherapy.
- More data will be presented at a medical meeting, Exelixis said.
- Price Action: EXEL shares are down 1.89% at $16.86 on the last check Friday.
- Photo Via Company
These 5 Experts See A Market Crash Ahead: What Do BZ Readers Think?
A majority of Benzinga readers, 63.5%, expect the S&P 500 to hit a new low in September, according to a recent survey. More than 36% say it won't.
